REFERENCES
1 – Ministério da Saúde, Brazil: Chikungunya clinical management. Brasília: 2017; 1: 1-67. https://bvsms.saude.gov.br/bvs/publicacoes/chikungunya_manejo_clinico.pdf. Accessed October 10, 2021.
2 - Getts MT, Miller SD: 99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: triggering of autoimmune diseases by infections. Clin. exp. immunol. 2010; 160: 15-21.
3- Vairo F, Haider N, Kock R, Ntoumi F, Ippolito G, Zumla A: Chikungunya: Epidemiology, Pathogenesis, Clinical Features, Management, and Prevention. Infect Dis Clin North Am. 2019; 33: 1003-25.
4- Castro APCR, Lima RAN, Santos J: Chikungunya: vision of the pain clinician. Revista Dor (online) 2016; 17: 299-302.
5- Martins HA, Bernardino SN, Santos CC, Ribas VR: Chikungunya and Myositis: A Case Report in Brazil. J Clin Diagn Res 2016; 10: OD05-06.
6- Choudhary N, Makhija P, Puri V, Khwaja GA, Duggal A: An Unusual Case of Myelitis with Myositis. J Clin Diagn Res 2016; 10: OD19-20.
7- Dalakas MC: Inflammatory myopathies: update on diagnosis, pathogenesis and therapies, and COVID-19-related implications. Acta myol 2020; 39: 289-301.
8- Dev N, Kumar R, Gogna A, Sharma S: Chikungunya-induced inflammatory myositis: a case report in India. Trop Doct 2019; 49: 241-3.
9 - Morrison TE, Oko L, Montgomery SA, et al.: A mouse model of chikungunya virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis, and persistence. Am J Pathol 2011; 178: 32-40.
10. Carboni RCS, Pinto GLB, Shinjo SK. High YKL-40 serum levels and its expression in the muscle tissues of patients with antisynthetase syndrome. Adv. Rheumal 2021; 61:44.